Compare Amphastar Pharmaceuticals Inc (AMPH) vs BlackRock TCP Capital Corp (TCPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs BlackRock TCP Capital Corp — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while BlackRock TCP Capital Corp trades at $3.9 (market cap $331.42M). The key difference: Amphastar Pharmaceuticals Inc is far larger — about 2.6× BlackRock TCP Capital Corp's market cap, and BlackRock TCP Capital Corp pays a 19.24% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | TCPC | |
|---|---|---|
Market Cap | $863.95M | $331.42M |
Sector | Health | Financials |
52-Week High | $30.81 | $7.26 |
52-Week Low | $16.87 | $3.13 |
Enterprise Value | $1.26B | — |
Dividend Yield | — | 19.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
TCPC trades at $4.11, up 5.38% in 24 hours, with a bullish technical signal from moving averages despite overbought RSI readings. The company reported Q2 2026 earnings of $0.22 per share, beating expectations, and announced a $523 million portfolio sale to reduce leverage. However, fundamentals show negative revenue and net income trends, with a net income margin of 118.75% reflecting significant losses relative to revenue.
The outlook is mixed: strategic actions like portfolio sales and dividend payments ($0.17 per share) support value, but persistent losses and class action lawsuits pose risks. Analyst consensus leans hold, with 30.77% buy ratings, indicating cautious optimism amid financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →
